Ciclosporin - Cellgate

Drug Profile

Ciclosporin - Cellgate

Alternative Names: CGC 1072; CGC 1072 analogue - Cellgate; CGC 2001; Cyclosporin modified - Cellgate; Cyclosporine modified - Cellgate; PsorBan

Latest Information Update: 09 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellgate
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis

Most Recent Events

  • 09 Aug 2007 Discontinued - Phase-II for Psoriasis in USA (Topical)
  • 05 May 2003 Clinical data from a media release have been added to the pharmacokinetics and the Skin Disorders and Drug Delivery Systems therapeutic trials sections
  • 09 Apr 2003 Data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) have been added to the adverse events and Skin Disorders and Drug Delivery Systems therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top